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In response to stress, cells induce ribonucleoprotein aggregates, termed stress granules (SGs).  40 
SGs are transient loci containing translation-stalled mRNA, which is eventually degraded or 41 
recycled for translation.  Infection of some viruses including influenza A virus with a 42 
deletion of non-structural protein 1 (IAVNS1) induces SG-like protein aggregates.  43 
Previously, we showed that IAVNS1-induced SGs are required for efficient induction of 44 
type I interferon (IFN).  Here, we investigated SG formation by different viruses using 45 
GFP-tagged Ras-GAP SH3 domain binding protein-1 (GFP-G3BP1) as an SG probe.  HeLa 46 
cells stably expressing GFP-G3BP1 were infected with different viruses and GFP 47 
fluorescence was monitored live with time-lapse microscopy. SG formation by different 48 
viruses was classified into 4 different patterns: no SG formation, stable SG formation, 49 
transient SG formation and alternate SG formation. We focused on EMCV infection, which 50 
exhibited transient SG formation. We found that EMCV disrupts SGs by cleavage of G3BP1 51 
at late stages of infection (>8 h) through a similar mechanism to that by poliovirus. 52 
Expression of a G3BP1 mutant, which is resistant to the cleavage, conferred persistent 53 
formation of SG as well as an enhanced induction of IFN and other cytokines at late stages of 54 
infection. Additionally, knockdown of endogenous G3BP1 blocked SG formation with 55 
attenuated induction of IFN and potentiated viral replication. Taken together, our findings 56 
suggest a critical role of SG as an antiviral platform and shed light on one of the mechanisms 57 
by which a virus interferes with host stress and subsequent antiviral responses.  58 
 59 
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In eukaryotic cells, viral infections induce several responses. Cellular pathogen recognition 64 
receptors such as RIG-I-like receptors (RLRs), and Toll-like-receptors recognize specific 65 
pathogen-associated molecular patterns and activate the transcription of hundreds of genes 66 
including interferons (IFNs), inflammatory cytokines and antiviral proteins. Secreted IFNs，in 67 
turn, activate a secondary JAK-STAT signaling cascade, which culminate in the activation of 68 
various interferon stimulated genes (ISGs) (1,2). A representative ISG, protein kinase 69 
RNA-activated (PKR), acts as an antiviral protein by inducing the blockade of viral 70 
translation (3-5).  PKR is also known to associate with cellular stress-responses.  Virus 71 
infection results in the accumulation of double-stranded RNA (dsRNA), thereby activating 72 
PKR and phosphorylation of eukaryotic initiation factor 2α (eIF2α), leading to the formation 73 
of stress granules (SGs) (6,7). Several studies have reported about the interaction between 74 
viruses and SGs, especially the effects of specific type of viruses on the fate of SG formation 75 
and how viruses modulate stress granule assembly (8-11). Recently, we reported that RLR 76 
recruitment to SGs during SG formation is critical in RLR-mediated signaling and 77 
non-structural protein 1 of influenza A virus blocks RLR signaling by inhibiting SG and 78 
antiviral response (12). Accumulating evidence suggests that viruses have evolved strategies 79 
to prevent SG formation. These results suggest that virus-induced SGs potentially serve as 80 
platforms for antiviral activity, however, the underlying molecular mechanism still remains to 81 
be elucidated.  82 
 In the present study, we aim to delineate the physiological impact of stress granule 83 
formation and its viral modulation. We employed an EGFP-tagged stress granule marker, 84 
Ras-Gap-SH3 domain binding protein (G3BP1) to probe the subcellular distribution of 85 
virus-induced SGs (13,14). This system allows us to monitor SGs in an individual 86 
virus-infected cell. Infection with RNA and DNA viruses displayed three distinct patterns: 87 
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stable, transient and alternate formation of SG. We focused on encephalomyocarditis virus 88 
(EMCV), which exhibited transient formation of SGs. We show that EMCV disrupts SGs 89 
through G3BP1 cleavage. Furthermore, we found that EMCV-induced SGs are required for 90 
efficient activation of IFN and cytokine genes. We propose a new antiviral concept 91 
highlighting the potential cross-talk of virus-induced stress responses and activation of the 92 
IFN signaling cascade. This may provide a new insight in understanding the mechanism by 93 
which antiviral genes are regulated.  94 
 95 
  96 
 5 
MATERIALS AND METHODS  97 
 98 
 99 
Plasmid constructs. The stress granule marker constructs pEGFP-C1-G3BP1 (NM_005754) 100 
was a kind gift from Dr. Jamal Tazi (Institute de Génétique Moléculaire de Montpellier, 101 
France). pEGFP-C1-G3BP1 Q325E mutant construct was generated by site-directed 102 
mutagenesis through KOD-Plus-Mutagenesis kit (TOYOBO, Japan), using primers 103 
containing the desired mutation according to manufacturer’s instructions, and were 104 
completely sequenced by using ABI Prism DNA sequencer to verify the presence of mutation. 105 
This plasmid contained a single point amino acid substitution at position 325 (from glutamine 106 
to glutamate), which is resistant to cleavage by 3C
PRO
 of Poliovirus (PolioV) (15).  107 
Expression vectors for EMCV pF-leader and pF-3C protease were described previously (16).  108 
 109 
Viruses. PolioV (Mahoney strain), vesicular stomatits virus (VSV, Indiana strain), EMCV, 110 
adenoviruses (Type5), Sindbis virus (SINV) and Theiler’s murine encephalomyelitis virus 111 
(TMEV, GDVII strain) were prepared by infecting BHK cells at a multiplicity of infection 112 
(MOI) of 1. Cell culture medium was collected after confirming cytopathic effects following 113 
infection. Medium containing newly produced viruses was centrifuged at 1,500rpm for 5 min 114 
to pellet down the cell debris, supernatant containing viruses were collected and stored at 115 
-80°C. Viral titer was assessed by plaque assay on L929 cells as previously described (17). 116 
NDV (Miyadera strain), Sendai virus (Cantell, SeV) and influenza A virus with a deletion of 117 
the NS1 gene (IAV∆NS1, strain A/Puerto Rico 8/34) (18,19) were propagated in the allantoic 118 
cavities of embryonated chicken eggs, then stocks were stored at -80°C.  119 
 120 
Generation of stable HeLa cells and general cell culture conditions.  Cell lines were 121 
maintained in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% 122 
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heat-inactivated fetal bovine serum (Nacalai Tesque, Japan) and Penicillin-Streptomycin 123 
(100U/mL and 100μg/mL respectively, Nacalai Tesque, Japan).  To generate HeLa cells 124 
stably expressing EGFP-G3BP1 wild type and Q325E mutant, pEGFP-C1-G3BP1 and 125 
pEGFP-C1-G3BP1 Q325E mutant expression constructs was linearized by restriction enzyme 126 
ApaL1 (Takara, Japan). The linearized plasmids were then transfected into HeLa cells using 127 
FuGENE6 (Promega, USA) according to manufacturer’s recommendations. Transformants 128 
were selected by including 1 mg/mL of G418 in the culture medium. Individual colonies 129 
were isolated and characterized.  130 
 131 
Live-cell imaging and immunofluorescence microscopy.  For the live-cell imaging 132 
analysis, HeLa cells stably expressing EGFP-G3BP1 (HeLa/G-G3BP) were seeded in 12-well 133 
plate and incubated at 37°C. After 24 hours, cells were washed with DMEM medium (10% 134 
fetal bovine serum and 1% Penicillin-Streptomycin) for several rounds. Cells were then 135 
infected with various types of RNA and DNA viruses. After 1 hour infection, virus was 136 
removed and replaced with 1.0 mL of DMEM imaging medium (4,500 mg/L D-glucose and 137 
L-glutamine, 25mM HEPES buffer, no sodium pyruvate and phenol red, Invitrogen). Imaging 138 
was immediately initiated every 10mins. Live cells were maintained on the microscope stage 139 
at 37°C, with 5% carbon-dioxide in a humidity-controlled chamber. Images were mounted 140 
using Biophotonics-ImageJ software. All imaging was performed by using a Leica CTR 141 
6500.    142 
 For the immunofluorescence analysis, cells were seeded either in a 12-well plate or a 143 
8-well chamber slide and incubated at 37°C. After 24 hours, cells were subjected to various 144 
treatments such as plasmid transfection or virus infection. Cells were then rinsed in 145 
phosphate-buffered saline (PBS) several times, fixed with 4% paraformaldehyde solution for 146 
10 min at room temperature, washed with PBS for two additional rounds, permeabilized with 147 
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acetone:methanol (1:1) for one minute, and blocked with phosphate-buffered saline 148 
containing 0.1 % Tween-20 (PBST) solution containing bovine serum albumin (BSA, 5.0 149 
mg/mL) for 1 hour at 4°C. Cells were then incubated with primary antibody, followed by 150 
fluorophores-conjugated secondary antibodies (Invitrogen) for one-hour at 4°C. Cells were 151 
washed with PBST extensively and mounted. All images were obtained by a Leica CTR 152 
6500.  153 
 154 
siRNA-directed gene silencing. The siRNA universal negative control and siRNA targeting 155 
stress granule marker-G3BP1 (50nM) and dsRNA protein kinase PKR were purchased from 156 
Invitrogen, and transfected using either Lipofectamine2000 (Invitrogen) or RNAiMax 157 
(Invitrogen) according to manufacturer’s recommendation. The sequence of siRNA: RIG-I, 158 
sense 5'-CGG AUU AGC GAC AAA UUU AUU-3', antisense 5'-UAA AUU UGU CGC 159 
UAA UCC GUU-3'; PKR#1, sense 5'-UUU ACU UCA CGC UCC GCC UUC UCG U-3', 160 
antisense 5'-ACG AGA AGG CGG AGCGUGAAGUAA A -3'; PKR#2, sense 5'- AUG UCA 161 
GGA AGG UCA AAU CUG GGU G-3', antisense 5'-CAC CCA GAU UUG ACC UUC CUG 162 
ACA U-3'; G3BP1, sense 5’-UAA UUU CCC ACC ACU GUU AAU GCG C-3’, antisense 163 
5’-GCGCAUUAACAGUGGUGGGAAAUUA-3’. After 48 hours post-transfection, cells 164 
were subjected to viral infection or other treatments. A specific antibody for G3BP1 (Santa 165 
Cruz) was used to monitor the knockdown efficiency.  166 
 167 
RNA analysis. RNA was harvested from cells with TRIzol (Invitrogen) according to the 168 
manufacturer’s instructions. Contaminating DNA was then eliminated by using recombinant 169 
DNase I (Roche, 10 units/μL) according to the manufacturer’s protocol. Treated samples 170 
were purified by phenol-chloroform extraction. 500 ng of purified RNA was used as a 171 
template to synthesize cDNA using a High Capacity cDNA Reverse-Transcription kit 172 
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(Applied Biosystem) as specified by the manufacturer through the following cycles: 25°C for 173 
10 seconds; 37°C for 2 hours; 85°C for 10 seconds. The concentration of cDNA was 174 
quantified by a spectrophotometer and the final concentration was adjusted to 1 μg/μL. 175 
cDNA samples were then either subjected to standard PCR or real-time quantitative-PCR 176 
analysis with specific probes from Taqman Gene Expression Assay (Applied Biosystem). 177 
Quantification of EMCV viral RNA was performed using SYBR master mix (Applied 178 
Biosystem) with specific primers targeting EMCV capsid coding region.  Standard PCR was 179 
performed with cDNA samples together with a master mix containing 1X PCR buffer, 180 
2.5mM of each dNTP’s, 0.2 units of ExTaq Polymerase and 1.0μM of both forward and 181 
reverse primers. PCR buffer, dNTPs and ExTaq Polymerases were purchased from Takara, 182 
Japan. Primers were all customized and purchased from Invitrogen. PCR was performed in 183 
50 μL reaction mixture with initial annealing temperature at 56°C-60°C. PCR products were 184 
analyzed by agarose gel electrophoresis.  185 
 186 
Western blotting.  Cells were collected in ice-cold PBS by scrapper. Cells were collected 187 
by centrifugation and lysed by NP-40 buffer (50mM Tris [pH8.0], 150mM NaCl, 1% 188 
[vol/vol] NP-40, 1 nM of Vanadate, 1 mM of Leupeptin and phenylmethanesulfonylfluoride), 189 
followed by centrifugation at 15,000rpm for 10 min and ultracentrifugation at 100,000rpm for 190 
5min. The supernatant was mixed with an equal volume of 2X SDS buffer, boiled for 5 min, 191 
separated by SDS-PAGE (30μg/lane), and transferred to nitrocellulose membrane. The 192 
membranes were incubated in blocking buffer (PBS, 5% [wt/vol] dry milk powder) for 30min 193 
at room temperature, followed by incubation with primary antibody diluted in blocking buffer 194 
at 4°C overnight. Membranes were washed extensively with TBST (TBS, 0.1% Tween-20), 195 
followed by incubation with a conjugated-secondary antibody for 1 hour at room temperature. 196 
The proteins were visualized using alkaline-phosphatase buffer containing BCIP-NBT 197 
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(Promega) color development substrate (100 mM Tris-HCl [pH9.0], 150 mM NaCl, 1 mM 198 
MgCl2, 66 μL of NBT [50 mg/mL] and 33 μL of BCIP [50mg/mL]).  199 
   200 
Antibodies.  The antibodies used in this study include mouse monoclonal anti-GFP (1:1000, 201 
MBL); goat polyclonal anti-G3BP1 (1:500, Santa Cruz sc-70283); mouse monoclonal 202 
anti-G3BP1 (1:1000, Santa Cruz sc-365338); rabbit polyclonal anti-PKR (1:1000, Santa Cruz 203 
sc-709); rabbit polyclonal anti-TIA1/R (1:1000, Santa Cruz sc-48371); goat polyclonal 204 
anti-TIAR (1:1000, Santa Cruz sc-1749); rabbit polyclonal anti-HuR (1:1000, Santa Cruz 205 
sc-365816); Propidium iodide [PI] (1:2000 in PBST, Miltenyi Biotec). The RIG-I antibody 206 
were generated by immunizing a rabbit with a synthetic peptide corresponding to amino acid 207 
793-807 of RIG-I and MDA5. Mouse monoclonal anti-PABP (1:1000, Abcam ab6125); 208 
rabbit monoclonal anti-actin (1:5000; BioLegend Poly6221); mouse anti-FLAG (1:1000, 209 
Sigma Aldrich) and rabbit monoclonal anti-phospho-PKR pT446 (1:1000, Epitomics Inc.). 210 
Anti-EMCV polyclonal antibody was obtained by immunizing a rabbit with purified EMCV 211 
virions. Anti-MDA5 polyclonal antibody was obtained by immunizing a rat with recombinant 212 
MDA5 (produced in insect cells) which was pre-activated with RNA ligands.  213 
 214 
Quantification for the distribution pattern of virus-induced SG. SG formation was 215 
quantified visually by using eye-sight counting. The total number of cells displaying each 216 
unique distribution pattern in each location was recorded and the percentage for each pattern 217 
was calculated. As for the fixed cells, 10 pictures at different locations were taken randomly. 218 
Cells displaying SG foci were quantified manually. Graphs display the average percentage of 219 
replicates (at least 20 times).  220 
 221 
 222 




Characterization of HeLa cells stably expressing SG marker, G3BP1. To monitor SGs in 226 
living cells, we generated HeLa/G-G3BP (Fig. 1). Constitutive aggregation of intrinsic SG 227 
components is reported to lead to a severe stall in protein synthesis and eventual apoptosis 228 
(14,20). All the HeLa/G-G3BP clones displayed uniform and high GFP expression and their 229 
growth rate was comparable to the parental cells (our unpublished observation). It has been 230 
well documented that G3BP1 accumulates in SG foci in response to arsenite treatment 231 
(oxidative stress) and virus infection (12,13). HeLa/G-G3BP clone 12 was treated with 232 
arsenite or infected with Newcastle disease virus (NDV) or Influenza A virus (IAV) with an 233 
NS1 deletion (IAVΔNS1), then the GFP localization was examined by confocal microscopy.  234 
As shown in Fig. 1A, speckle-like localization of GFP was induced by these stimuli.  Other 235 
clones also exhibited similar speckle formation after arsenite treatment or NDV infection (Fig. 236 
1B, C). We confirmed that other SG components, TIA-1, TIAR, HuR and eIF3 colocalized 237 
with the GFP speckles (unpublished observation). These results indicate that EGFP-G3BP1 238 
acts as a suitable probe for virus-induced SGs. However, since transient overexpression of 239 
G3BP1 results in SG formation without external stress (13), we tested if the HeLa/G-G3BP 240 
clones would exhibit normal antiviral response. As shown in Fig. 1D, all clones exhibited 241 
comparable induction of IFN-β mRNA as parental cells. We chose clone 18 for further 242 
analyses.  243 
 244 
G3BP1 exhibits three redistribution patterns after infection with both RNA and DNA 245 
viruses. To examine the dynamics of cytoplasmic SGs induced by viral infection, the cells 246 
were infected with different viruses as shown in Fig. 2 and monitored live for distribution of 247 
GFP fluorescence (representative results are shown in Movie S1-S9). Cells infected with SeV, 248 
IAV, VSV and TMEV did not show SG formation (8). Other viruses induced SGs, typically 249 
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forming a large number of small granules around 5 h post infection and gradually fusing to 250 
each other.  SG formation was quantified (Fig. 2A-K) and classified into three predominant 251 
patterns: stable formation (Fig. 2L), transient formation (Fig. 2M), and alternating formation 252 
(Fig. 2N) within a single cell. NDV, IAVΔNS1 and Adenovirus 5 displayed a stable 253 
formation of SGs (Movie S1-S3). Whereas SINV, EMCV and PolioV induced foci at around 254 
5 to 6 h post infection, however, the foci disappeared thereafter (transient formation) (Fig. 255 
2D-2F; Movie S4-S6). Interestingly, adenovirus 5 with E1A deletion, exhibited multiple 256 
rounds of formation and disappearance of SGs (alternate formation) in the majority of cells 257 
(Fig. 2I; Movie S7). Similar oscillation of SGs in cells infected with HCV and treated with 258 
IFN was reported (21). Collectively, these live-cell imaging analyses demonstrated that viral 259 
infections trigger host stress responses, however different viruses induce distinct response 260 
patterns, presumably through specific underlying mechanisms. The observed SG formation 261 
patterns are unlikely due to G3BP1 overexpression because wt HeLa cells exhibited transient 262 
SG formation upon EMCV infection when endogenous G3BP1 was used as a marker (Fig. 263 
2O). 264 
 265 
EMCV infection results in the cleavage of G3BP1. We focused on the mechanism of 266 
transient formation of SGs by EMCV because PolioV has been reported to inhibit SG 267 
formation by cleavage of G3BP1 (15). We examined if EGFP-G3BP1 is cleaved by EMCV 268 
by Western blotting. EGFP-G3BP1 fusion protein is detected as a polypeptide of 96 kDa and 269 
EMCV infection resulted in the appearance of an 80 kDa GFP-containing protein at 6 h post 270 
infection and nearly complete cleavage of EGFP-G3BP1 reached near completion at 10 h 271 
post infection (Fig. 3A). Because the fusion protein contains an EGFP moiety at the 272 
N-terminus of G3BP, the cleavage of G3BP1 is likely to occur at the C-terminal region of 273 
G3BP1. We verified the cleavage site by using an antibody detecting the C-terminal epitope 274 
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of G3BP1 (Fig. S1A and B).  Because the mapped cleavage site was close to that by PolioV 275 
and the cleavage by PolioV is prevented by amino acid substitution within G3BP1 (Q325E) 276 
(15), we therefore examined this mutant for cleavage by EMCV (Fig. 3B). We found that 277 
G3BP1 Q325E was resistant to cleavage by EMCV, suggesting a common cleavage 278 
mechanism. To examine whether the disruption of SG by EMCV is solely due to cleavage of 279 
G3BP1, we examined other SG components, PABP, TIA-1/R, HuR and PKR, which are also 280 
essential for SG formation. Fig. 3C shows that the levels of SG components with the 281 
exception of G3BP1 did not change upon EMCV infection and that G3BP1 cleavage 282 
coincided with the detection of EMCV proteins. Expression of EMCV 3C protease but not 283 
leader protein by transfection was sufficient to reproduce G3BP1 cleavage at Q325 (Fig. 3D), 284 
strongly suggesting that the cleavage is mediated by 3C protease.  We next examined SG 285 
formation of HeLa/G-G3BPQ325E.  In sharp contrast to the cells expressing wild type 286 
G3BP1 (Movie S6), HeLa/G-G3BPQ325E exhibited stable formation of SGs as judged by 287 
single cell imaging (Fig. 4A and B; Movie S8) and quantification (Fig. 4C). These results 288 
suggest that EMCV disrupts SGs by cleavage of G3BP1 through a similar mechanism as 289 
PolioV.    290 
 291 
G3BP1 negatively regulates EMCV replication. To examine the impact of SG disruption 292 
on EMCV replication, we infected both HeLa/G-G3BP and HeLa/G-G3BPQ325E with 293 
EMCV and analyzed viral replication by RT-qPCR (Fig. 5A). EMCV RNA recovered from 294 
HeLa/G-G3BP was six fold higher compared with that of HeLa/G-G3BPQ325E. Similarly, a 295 
significantly lower viral yield was observed with cells expressing G3BP1 Q325E, suggesting 296 
that SG formation is critical for suppressing EMCV replication. To further confirm the 297 
involvement of G3BP1, we depleted endogenous G3BP1 by siRNA-mediated knockdown 298 
(Fig. 5B) and examined its effect on EMCV replication. G3BP1 knockdown caused increased 299 
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EMCV replication as judged by the approximate 5-fold augmentation of viral RNA and viral 300 
yield (Fig. 5B). These results suggest that G3BP1 is involved in the negative regulation of 301 
EMCV.   302 
 303 
G3BP1 is critical for EMCV-induced interferon and cytokine gene activation. Based on 304 
the above findings, we next asked how G3BP1 exerts its antiviral role. The type I interferon 305 
system constitutes major innate antiviral responses, therefore we examined EMCV-induced 306 
IFN-β gene activation in HeLa/G-G3BP and HeLa/G-G3BPQ325E (Fig. 6). In 307 
HeLa/G-G3BP cells, IFN-β mRNA accumulated at 4 h post infection, followed by a gradual 308 
decrease.  However, IFN-β mRNA levels persisted in HeLa/G-G3BPQ325E after 8 h post 309 
infection (Fig. 6B).  In agreement with these results, the amount of IFN-β protein released 310 
into the culture medium at 24 h is significantly augmented by Q325E mutation (Fig. 6A).  311 
Similar enhancement of cytokine mRNA was observed for CXCL10, IL-6 and RANTES (Fig. 312 
6C-E). We investigated gene activation at early time points between 0 to 4 h, and observed 313 
similar activation kinetics between HeLa/G-G3BP and HeLa/G-G3BPQ325E (Fig. 7), 314 
suggesting that the reduced gene activation of HeLa/G-G3BP is due to G3BP1 cleavage. 315 
Q325E mutation did not affect the IFN-β gene induction in the case of IAVΔNS1, which did 316 
not cause G3BP1 cleavage (Fig. 6F). Next, we examined the effects of depleting endogenous 317 
G3BP1 on cytokine gene activation. As expected, knockdown of endogenous G3BP1 318 
attenuated IFN-β and other cytokine gene expression (Fig. 8A-D). These results strongly 319 
suggest that G3BP cleavage leads to attenuation of antiviral cytokine induction.  320 
It has been well documented that MDA5 senses EMCV infection (22-25), and that 321 
virus- and oxidative stress-induced SGs recruit RIG-I, MDA5 and LGP2 (12). Therefore, we 322 
hypothesized that EMCV-induced SG regulates IFN-β gene activation by facilitating MDA5 323 
activation. We examined MDA5 localization in EMCV-infected HeLa cells by 324 
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immunostaining. MDA5 displayed re-localization to speckle-like granules upon EMCV 325 
infection (Fig. 9A). The speckles also contain endogenous G3BP1 (Fig. 9A) and TIAR (Fig. 326 
9B). Interestingly, PI, a dye that binds to dsDNA and dsRNA, stains cytoplasmic speckles 327 
found only in virus-infected cells and the dsRNA speckles are co-localized with G3BP1 and 328 
TIAR. These observations suggest that EMCV infection induces SGs, which recruit SG 329 
markers, MDA5 and EMCV dsRNA. 330 
 331 
PKR is essential for SG-formation and IFN-induction in EMCV infection. Various types 332 
of viruses were shown to induce SG formation through PKR activation (26-28).  We 333 
therefore examined whether EMCV induces SG formation in a PKR-dependent manner. 334 
Endogenous PKR expression was efficiently downregulated by siRNA (Fig. 10A).  Under 335 
these conditions, SG formation by EMCV was decreased significantly (Fig. 10A). We next 336 
asked whether cleavage of G3BP1 results in PKR dephosphorylation. Immunoblot analyses 337 
showed that PKR was autophosphorylated at 4 h post infection, however at 12 h, when 338 
G3BP1 cleavage was nearly complete, PKR phosphorylation was undetectable (Fig. 10B, 339 
Lane 3), suggesting that G3BP1 cleavage resulted in PKR dephosphorylation. Finally, we 340 
examined whether the final outcome of the signaling, IFN-β gene expression, was dependent 341 
on PKR.  In PKR knockdown cells, the induction of IFN-β mRNA by EMCV was 342 
significantly decreased compared to control cells (Fig. 10C). We further confirmed previous 343 
reports that IFN induction by PolyI:C or IAVΔNS1 infection was PKR dependent (12). From 344 
the data presented above, we concluded that loss of PKR impaired EMCV-induced SG 345 
formation, leading to a reduction of IFN-β gene activation.  346 
  347 
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DISCUSSION 348 
Viral infection causes stress in host cells, resulting in SG formation. To date, both pro- and 349 
anti-viral roles have been described for virus-induced SGs (28-30) and this issue remains 350 
controversial.  351 
In this study, we demonstrated that SGs are potentially involved in mediating 352 
virus-triggered IFN responses. It was reported that PolioV 3C protease cleaves G3BP1 at the 353 
residue of Q325, resulting in the disruption of SGs (15). The observation indicates that 354 
G3BP1 is not only a component of SGs but also its inactivation by cleavage causes the 355 
disruption of SGs. Here, we show that EMCV shares G3BP cleavage activity with identical 356 
specificity to PolioV 3C requiring intact Q325. Interestingly, Coxsackie virus also disrupts 357 
SG (31) by a similar mechanism (Fung et al unpublished observation), suggesting that this 358 
strategy is shared by some picornaviruses to evade immune responses. At the early phase of 359 
EMCV infection, cleavage of G3BP1 was not evident. However, at 4 hpi, cleavage was 360 
detectable, and at 10 h, cleavage reached completion, suggesting that the accumulation of 3C 361 
is necessary for the disruption. We observed that stable expression of G3BP1 Q325E blocked 362 
the disassembly of SGs as well as enhanced IFN-β production at a late phase of infection. 363 
Furthermore, knockdown experiments showed that G3BP1 is necessary for efficient 364 
activation of the IFN-β gene, particularly at the later stages of infection. Although it was 365 
reported that PolioV 3C cleaves RIG-I and MDA5 (32), and EMCV cleaves RIG-I (33), we 366 
did not observe these cleavages even under the conditions in which G3BP1 was cleaved by 367 
EMCV or PolioV (Fig. 11).  Taken together, we conclude that G3BP1 is a physiological 368 
regulator of IFN-β gene induction through the formation of SGs, which recruits the RNA 369 
sensor MDA5. In addition, the persistent activation of the IFN-β gene at late time points is 370 
likely due to the increase of the local concentration of both MDA5 and its ligands within the 371 
condensed granules.   372 
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Collectively, the data presented above strongly suggest that 3C protease of EMCV 373 
acts as critical factor for evading host IFN production to ensure efficient replication. It was 374 
demonstrated that PKR plays a critical role in dsRNA- or IAVΔNS1-induced SG formation 375 
and subsequent IFN-β gene activation (12). Our observation that PKR is required for efficient 376 
IFN gene activation by EMCV, suggests that PKR is responsible for initiating the SG 377 
formation (Fig. 10).  378 
Considering that the assembly of SGs is a part of antiviral response of the host, it is 379 
plausible that viruses evolve strategies to block it. Indeed, IAV, SeV and TMEV do not 380 
induce SG (Fig. 2) and it was reported that leader RNA, NS1 and leader protein are 381 
responsible for the inhibition, respectively (8,12,34). Although TMEV belongs to 382 
Picornaviridae, their mechanism of SG inhibition appeared to be distinct from those of 383 
EMCV and PolioV.  TMEV and Mengovirus inhibit SG by the action of leader protein 384 
(8,31). We found that 3C but not the leader protein of EMCV inhibits SG formation (Fig. 12). 385 
It is tempting to speculate that leader of TMEV and Mengovirus inhibit IFN production 386 
(35,36) through the blockade of SG formation, where RLR and viral RNA efficiently interact, 387 
as one of the mechanisms. Interestingly, although the leader of EMCV did not affect SGs, it 388 
inhibits IFN gene activation (Fig. 12), suggesting that leaders of different cardioviruses are 389 
functionally equivalent (37,38), however through distinct mode of action. Therefore, these 390 
viruses encode multiple inhibitory proteins to efficiently manipulate host immune responses.  391 
EMCV and SINV induced SG at early time points after infection but the SG formation was 392 
disrupted later. A similar phenomenon was reported for West Nile and Dengue viruses by 393 
monitoring TIA-1/R as a SG marker (29). In the case of EMCV and PolioV, G3BP1 cleavage 394 
by viral 3C protease is responsible for the disassembly of the SG. Therefore, active 395 
mechanisms for the disruption of SGs by SINV, West Nile and Dengue viruses have been 396 
suggested, although underlying mechanisms remain to be determined. In addition to transient 397 
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formation of SGs, some viruses exhibited alternating formation of SGs; SGs were formed at 398 
an early stage then disappeared and re-formed at a later stage. This alternating pattern is also 399 
dependent on the cell lines used (unpublished observation), suggesting that the pattern of SG 400 
formation is determined by a dynamic balance between host antiviral response and viral 401 
inhibitory mechanism (21). Such a host mechanism could be a therapeutic target to enhance 402 
host defense against viruses.  403 
Here we provide evidence that EMCV-induced SGs are involved in regulating IFN-β 404 
gene expression. Thus, virus-induced SGs might play dual roles: (i) suppressing viral 405 
replication through an inhibition of viral protein synthesis, and (ii) serving as a platform to 406 
facilitate IFN-β production.  407 
 408 
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Figure Legends  541 
 542 
FIG 1. Characterization of HeLa/G-G3BP cells.  (A) HeLa/G-G3BP1 clone 12 was mock 543 
treated or stimulated as indicated.  Cells were fixed and examined for GFP fluorescence. 544 
Four independent HeLa/G-G3BP cell clones were stimulated by arsenite (B) or by infection 545 
with NDV (C) and % of GFP speckle positive cells was determined.  (D) Parental HeLa 546 
cells and HeLa/G-G3BP1 clones were infected with NDV for 12 h and IFN -β gene 547 
expression was determined by RT-qPCR. (Error bars, ±S.D. of duplicates, N=2). 548 
 549 
FIG 2. Three major forms of virus-induced stress granule distribution pattern in 550 
HeLa/G-G3BP cells infected with different viruses.  HeLa/G-G3BP cells were infected 551 
with (A) NDV, (B) IAV, (C D) EMCV, (E) SINV, (F) PolioV, (G) SeV, (H) 552 
VSV, (I) adenovir J) adenovirus 5 wild type 553 
(Adeno5WT) and (K) TMEV for 9~12 h and SG formation was monitored and quantified as 554 





P<0.05.  Representative cell images taken at the indicated time after 556 
infection, for stable (L, NDV), transient (M, SINV) and alternating (N557 
formation are shown. Wild type HeLa cells were mock infected or infected for 4 or 12 h and 558 
fixed to examine localization of endogenous G3BP1 by immunostaining (O). 559 
 560 
FIG 3. EMCV infection results in the cleavage of G3BP1. (A) Immunoblotting showing 561 
the kinetics of G3BP1 cleavage in EMCV-infected HeLa/G-G3BP1 cells. (B) HeLa stably 562 
expressing FLAG-G3BP1Q325E was infected with EMCV and G3BP1Q325E protein level 563 
was monitored by immunoblotting. (C) Western blot analysis of HeLa/G-G3BP1 cells 564 
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infected with EMCV. Lysates were prepared at the indicated time points after infection and 565 
subjected to immunoblotting by the indicated antibodies. (D) HeLa cells were transiently 566 
transfected with empty vector or expression vector for leader or 3C and analyzed for 567 
endogenous G3BP1 by Western blotting (left). HeLa/G-G3BP1 and HeLa/G-G3BP1Q325E 568 
were transiently transfected with empty vector or expression vector for leader or 3C and 569 
analyzed by Western blotting using anti GFP (right). 570 
 571 
FIG 4. HeLa/G-G3BPQ325E cells displayed stable formation of SG induced by EMCV 572 
infection. Both HeLa/G-G3BP1 (A) and HeLa/G-G3BP1Q325E (B) cells were infected with 573 
EMCV.  GFP fluorescence image of these cells at every 40 min is shown.  (C) Quantitative 574 
analysis of SG formation pattern of HeLa/G-G3BP1Q325E cells infected with EMCV. (Error 575 




FIG 5. Cleavage or knockdown of G3BP1 results in enhanced EMCV replication. (A) 578 
HeLa/G-G3BP1 and HeLa/G-G3BP1Q325E cells were infected with EMCV. Total RNA was 579 
harvested at 12 h post infection and EMCV RNA was quantified by qPCR (upper). The 580 
culture supernatant was subjected to plaque titration (lower). (B) HeLa cells were either 581 
transfected with control siRNA or that targeted to G3BP1. After 48 h, G3BP1 was detected 582 
by Western blotting (upper left) or by staining using anti G3BP1 antibody (upper right).  To 583 
investigate the effect of G3BP1 knockdown on viral replication, the cells were infected with 584 
EMCV for 12 h and total RNA was extracted and EMCV RNA was quantified by qPCR 585 
(bottom left). The culture supernatant was analyzed for viral titer (bottom right).  586 
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FIG 6. Inhibition of G3BP1 in EMCV-infected cells results in sustained 587 
cytokine/chemokine mRNA accumulation. HeLa/G-G3BP1 and HeLa/G-G3BP1Q325E 588 
cells were infected with EMCV. Culture supernatant was subjected to ELISA for IFN-β (A). 589 
Total RNA was harvested at the indicated time points. mRNAs for (B) IFN-β, (C) CXCL10, 590 
(D) IL-6 and (E) RANTES were determined by RT-qPCR. (F) Both HeLa/G-G3BP and 591 
HeLa/G- -β mRNA was quantified 592 
-infected HeLa/G-G3BP1 cells were examined for 593 
cleavage of G3BP1 by Western blotting (right). Data depicted are the representative of two 594 






FIG 7. IFN production and cytokine gene activation in HeLa/G-G3BP and 597 
HeLa/G-G3BPQ325E cells at early phase. HeLa/G-G3BP1 and HeLa/G-G3BP1Q325E 598 
cells were mock-treated or infected with EMCV for indicated time. Total RNA was extracted 599 
and mRNA was quantified for IFN-b (A), CXCL10 (B), IL-6 (C) and RANTES (D) by 600 
RT-qPCR. 601 
 602 
FIG 8. Knockdown of G3BP1 attenuates EMCV-induced cytokine/chemokine gene 603 
activation. HeLa cells were either transfected with control siRNA or that targeted to G3BP1.  604 
After 48 h of incubation, cells were infected with EMCV for 12 h and total RNA was 605 
collected as indicated. mRNAs for (A) IFN-β, (B) RANTES, (C) CXCL10 and (D) IL-6 were 606 
determined by RT-qPCR. Data are representative of two independent experiments. (Error bar, 607 
±S.D. of duplicates, N=2). 
*
P<0.05.  608 
 609 
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FIG 9. EMCV infection recruits MDA5 into SGs. HeLa cells were mock-treated or 610 
infected with EMCV (MOI: 10) and fixed. The cells were stained for MDA5, G3BP1 and PI 611 
(A) or MDA5, TIAR and PI (B). 612 
 613 
FIG 10.  Involvement of PKR in EMCV-induced SG and IFN-β gene activation. (A) 614 
Knockdown of PKR expression results in reduced SGs. HeLa cells transfected with siRNA 615 
targeting PKR for 48 h was examined for PKR expression by Western blotting (left). The 616 
cells were infected with EMCV for 6 h and stained for endogenous G3BP1 (middle). 617 
SG-containing cells were quantified (right). (B) HeLa cells infected with EMCV for 0, 4 and 618 
12 h were analyzed for G3BP1, phospho-PKR, EMCV proteins and actin by immunoblotting.  619 
(C) HeLa cells transfected with siRNA targeting PKR for 48 h was mock treated or 620 
transfected with poly I:C or infected with IAV∆NS1 or with EMCV. After 12 h, IFN mRNA 621 




P<0.05.  622 
 623 
FIG 11. RIG-I was not cleaved after EMCV or PolioV infection. (A) HeLa cells were 624 
either mock treated or infected with EMCV for indicated time. RIG-I was detected by 625 
Western blotting. (B) HeLa cells were mock treated or infected with Polio V for 9 h.  626 
G3BP1 (left) and RIG-I (right) were examined by Western blotting.   627 
 628 
FIG 12. EMCV 3C, but not leader inhibits SG. (A) HeLa/G-G3BP1 and 629 
HeLa/G-G3BP1Q325E were transiently transfected with empty vector or expression vector 630 
for leader or 3C for 48 h. Cells were treated with 0.5 mM Sodium arsenite for 30min, fixed 631 
and stained for TIAR, a SG marker. (B) HeLa cells were transiently transfected with empty 632 
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vector or expression vector for leader or 3C (0μg, 2μg and 4μg) for 48 h. Cells were mock 633 
treated or transfected with long polyI:C (2μg/μL) for 12 h. Total RNA was collected and 634 
mRNA for IFN-β was determined using RT-qPCR. Data are representative of three 635 
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Supplemental  FIG S1.  
FIG S1. Detection of C-terminal cleavage product of G3BP. HeLa/G-G3BP1 cells were either mock 
treated or infected with EMCV. (A) Cell lysate was prepared at 0, 8, 12 h post infection and analyzed 
by Western blotting using antibodies against C-terminal region of G3BP1 or b-actin. (B) Cleavage site 
within the domain structures of G3BP1.  
 
Supplemental Movie Legends  
Movie S1. Real-time imaging of stress-granule marker, G3BP1 after NDV infection. HeLa/G-
G3BP cells were either mock-treated or infected with NDV. Live-cell imaging was initiated after 1 h 
post-infection with images captured every 10 min. Fluorescence images at indicated time after 
infection are shown. 
 
Movie S2. Real-time imaging of stress-granule marker, G3BP1 after IAVΔNS1 infection. 
HeLa/G-G3BP cells were either mock-treated or infected with IAVΔNS1. Live-cell imaging was 
initiated after 1 h post-infection with images captured every 10 min. Fluorescence images at indicated 
time after infection are shown. 
 
Movie S3. Real-time imaging of stress-granule marker, G3BP1 after Adeno5WT infection. 
HeLa/G-G3BP cells were either mock-treated or infected with Adeno5WT. Live-cell imaging was 
initiated after 1 h post-infection with images captured every 10 min. Fluorescence images at indicated 
time after infection are shown. 
 
Movie S4. Real-time imaging of stress-granule marker, G3BP1 after SINV infection. HeLa/G-
G3BP cells were either mock-treated or infected with SINV. Live-cell imaging was initiated after 1 h 
post-infection with images captured every 10 min. Fluorescence images at indicated time after 
infection are shown.  
 
Movie S5. Real-time imaging of stress-granule marker, G3BP1 after PolioV infection. HeLa/G-
G3BP cells were either mock-treated or infected with PolioV (MOI=1). Live-cell imaging was 
initiated after 1 h post-infection with images captured every 10 min. Fluorescence images at indicated 
time after infection are shown. 
 
Movie S6. Real-time imaging of stress-granule marker, G3BP1 after EMCV infection. HeLa/G-
G3BP cells were either mock-treated or infected with EMCV (MOI=10). Live-cell imaging was 
initiated after 1 h post-infection with images captured every 10 min. Fluorescence images at indicated 
time after infection are shown. 
 
Movie S7. Real-time imaging of stress-granule marker, G3BP1 after Adeno5ΔE1A infection. 
HeLa/G-G3BP cells were either mock-treated or infected with Adeno5ΔE1A. Live-cell imaging was 
initiated after 1 h post-infection with images captured every 10 min. Fluorescence images at indicated 
time after infection are shown. 
 
Supplemental Movie Legends  
Movie S8. Real-time imaging of stress-granule marker, G3BPQ325E mutant stable cells after 
EMCV infection. HeLa/G-G3BPQ325E cells were either mock-treated or infected with EMCV 
(MOI=10). Live-cell imaging was initiated after 1 h post-infection with images captured every 10 min. 
Fluorescence images at indicated time after infection are shown. 
 
Movie S9. Real-time imaging of stress-granule marker, G3BP1 after TMEV infection. HeLa/G-
G3BP cells were either mock-treated or infected with TMEV (MOI=10). Live-cell imaging was 
initiated after 1 h post-infection with images captured every 10 min. Fluorescence images at indicated 
time after infection are shown. 
 
FIG S1. Detection of C-terminal cleavage product of G3BP. HeLa/G-G3BP1 cells were either mock 
treated or infected with EMCV. (A) Cell lysate was prepared at 0, 8, 12 h post infection and analyzed 
by Western blotting using antibodies against C-terminal region of G3BP1 or b-actin. (B) Cleavage site 















clone#12 clone#18 clone#39 clone#42 
Mock 






















clone#12 clone#18 clone#39 clone#42 
Mock 















































































































































































































































































































































































































































































G3BP1 DAPI MERGE 





EGFP-G3BP1 cp (≈ 80 kDa) 










































































































































0 8 12 EMCV 
HeLa 



























































































































































































































































































































































0 4 8 12 16 
siG3BP1 
siControl 



























































































G3BP1 MDA5 PI DAPI MERGE 
A 
B 















































































































0 4 12 
IB: α-G3BP1 (C-14) 
IB: α-EMCV 
proteins 
IB: α-actin β-actin 
1 2 3 
p.h.i  
EMCV 









IB: α-actin  
0 8 12 
HeLa 
EMCV h.p.i 
1 2 3 
β-actin 























1 2 3 
IB: α-RIG-I CTD 
IB: α-actin 





S-A: Mock with shRIG-I 
S-B: Mock infection 


















































































































- - EMCV 3C 
Mock PolyI:C 
HeLa 
A 
B 
FIG. 12 
